Peter Attia· MD
we learned a lot from rare diseases I think this is a case where we're learn lot example in in this case we already have a abundance of human genetic data that suggest this sort of polygenic version of this thing
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
we learned a lot from rare diseases I think this is a case where we're learn lot example in in this case we already have a abundance of human genetic data that suggest this sort of polygenic version of this thing
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
so I do think there will be targeted therapies and we'll test one sooner than later um we'll probably Begin by testing it in patients with lipid distrophy but the hope and expectation is that we'll move beyond that and and to eventually try and Target other metabolic Associated diseases and ultimately the most metabolic Associated disease which is you know Corner disease